share_log

AbbVie | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

AbbVie | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

艾伯維公司 | S-8：員工福利計劃證券登記
美股SEC公告 ·  08/14 16:11

Moomoo AI 已提取核心訊息

AbbVie Inc., a biopharmaceutical company incorporated in Delaware, has successfully completed the acquisition of Cerevel Therapeutics Holdings, Inc. on August 1, 2024, as per the Merger Agreement dated December 6, 2023. Following the merger, AbbVie has filed a Registration Statement on Form S-8 with the United States Securities and Exchange Commission to register shares of common stock that may be issued under the Cerevel 2020 Equity Incentive Plan. This plan has been assumed by AbbVie, and certain restricted stock unit awards previously granted under the plan have been converted into awards for AbbVie common stock. These converted awards will continue to be governed by the terms of the Cerevel Plan post-merger. The registration of these shares enables the settlement of the converted awards for AbbVie employees who held equity in Cerevel.
AbbVie Inc., a biopharmaceutical company incorporated in Delaware, has successfully completed the acquisition of Cerevel Therapeutics Holdings, Inc. on August 1, 2024, as per the Merger Agreement dated December 6, 2023. Following the merger, AbbVie has filed a Registration Statement on Form S-8 with the United States Securities and Exchange Commission to register shares of common stock that may be issued under the Cerevel 2020 Equity Incentive Plan. This plan has been assumed by AbbVie, and certain restricted stock unit awards previously granted under the plan have been converted into awards for AbbVie common stock. These converted awards will continue to be governed by the terms of the Cerevel Plan post-merger. The registration of these shares enables the settlement of the converted awards for AbbVie employees who held equity in Cerevel.
艾伯維公司是一家生物製藥公司，總部位於特拉華州，於2024年8月1日成功完成對cerevel therapeutics holdings的收購，根據於2023年12月6日簽訂的合併協議。合併後，艾伯維已向美國證券交易委員會申請S-8表格進行註冊，以註冊根據cerevel 2020股權激勵計劃發行的普通股股票。該計劃已被艾伯維公司批准，並且該計劃之前已授予的某些限制性股票單位獎勵已被轉換爲艾伯維普通股的獎勵。這些轉換後的獎勵將繼續受到合併後的cerevel計劃條款的管轄。這些股票的註冊使持有cerevel股權的艾伯維員工得以解決轉換後的獎勵事宜。
艾伯維公司是一家生物製藥公司，總部位於特拉華州，於2024年8月1日成功完成對cerevel therapeutics holdings的收購，根據於2023年12月6日簽訂的合併協議。合併後，艾伯維已向美國證券交易委員會申請S-8表格進行註冊，以註冊根據cerevel 2020股權激勵計劃發行的普通股股票。該計劃已被艾伯維公司批准，並且該計劃之前已授予的某些限制性股票單位獎勵已被轉換爲艾伯維普通股的獎勵。這些轉換後的獎勵將繼續受到合併後的cerevel計劃條款的管轄。這些股票的註冊使持有cerevel股權的艾伯維員工得以解決轉換後的獎勵事宜。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間